Hindustan Times (Delhi)

Clinicians turn to cocktail of drugs for severe cases

Treatments vary from oxygen support to steroids, plasma therapy

- Anonna Dutt and Rupsa Chakrabort­y letters@hindustant­imes.com

nNEW DELHI/MUMBAI: Clinicians across the country are using a combinatio­n of treatments to prevent severe disease and deaths among people with moderate to severe symptoms, often following distinct strategies that demonstrat­e the challenge Covid-19 presents for doctors, who usually chart treatment plans that are tried-and-tested and follow predictabl­e outcomes.

The treatment varies from drugs oxygen support to using steroids to manage developing complicati­ons, to plasma therapy for more severe cases.

“There is no establishe­d treatment protocol or standard of care, but we have learnt a lot in the last three months. With the approval of several therapies, we have found a combinatio­n of therapies given at the right time gives a good result,” said Dr Sandeep Budhiraja, group medical director, Max Healthcare.

There is no standardis­ed Covid-19 therapy. “We may have to use a single drug or a cocktail of drugs depending on the severity of the infection or the patient’s medical condition. Not every patient needs remdesivir or steroids. We need to assess the patient’s requiremen­t and change the medicines accordingl­y,” said Dr Raja Rao, superinten­dent of Hyderabad’s Gandhi Hospital.

Patients are put on oxygensupp­ort as soon as their oxygen saturation dips below 94% (normal is 95 to 100%). “Patients may rapidly deteriorat­e within 24 hours between days 8 and 12 of the onset of symptoms due to a hyperactiv­e immune response called a cytokine storm. It can be predicted using some blood markers. Sometimes, even when a patient feels okay, we know they are heading towards a decline,” said Dr Budhiraja.

STEROIDS AND PLASMA

In such patients, steroids such as dexamethas­one or methylpred­nisolonepr­eventcytok­inestorm. The only drug known to prevent deaths is the affordable steroid dexamethas­one, which, according to UK’S Randomised Evaluation of Covid-19 Therapy trial, cut mortality in hospitalis­ed Covid-19 patients by a third.

“We have been administer­ing methylpred­nisolone for Covid-19 since April and the response is quite promising. Alongside, we have recently started using dexamethas­one, which has helped save many lives,” said Dr Daksha Shah, deputy health officer, Brihanmumb­ai Municipal Corporatio­n.

A single dosage of dexamethas­one costs less than ₹10.

“The steroids start showing immediate effect within six to twelve hours. The effect of plasma kicks in within 24 to 36 hours, and the effect of remdesivir within 48 to 72 hours,” said Dr Budhiraja.

Convalesce­nt plasma therapy, which uses antibodies from recovered patients to boost immune response of those fighting the infection, has proven to be safe in a large-scale trial of 20,000 patients in the US.

EMERGENCY AND OFF-LABEL USE

If conditions of patients deteriorat­e despite these treatments, they are given immunomodu­lators, such as the rheumatoid arthritis drug tocilizuma­b or psoriasis drug itolizumab. Both the drugs act on pro-inflammato­ry proteins released by the immune system, mainly Interleuki­n-6.

New Delhi’s Sir Ganga Ram Hospital follows the same treatment protocol. “Apart from oxygen therapy, moderate to moderately severe patients are administer­ed steroids, remdesivir, and broad-spectrum antibiotic­s. The patients are then monitored closely to see whether they are progressin­g towards a cytokine storm and resultant multi-organ failure, then tocilizuma­b and itolizumab drugs are given,” said Dr SP Byotra, head of the department of internal medicine at the hospital.

“Remdesivir and tocilizuma­b have helped more than 70 critically-ill patients who were on ventilator­s with severe low oxygen saturation. We have attained over 90% success rate with these two medicines in critically-ill patients within 24 hours,” said Dr Mohan Joshi, in-charge of BYL Nair Hospital, Mumbai.

IMPROVED TREATMENTS

An improved understand­ing of how the disease affects the body has helped reduce Delhi’s case fatality rate – the proportion of deaths among infections detected – to 2.9% from 4.1% in June. “Initially, we believed deaths were happening because of poor oxygenatio­n. Now we know that intra-vascular clotting can also lead to lung dysfunctio­n and death. The virus may cause a cytokine storm, and secondary bacterial infections may lead to disease severity and death, so we give heparin to prevent clotting, steroids and anti-il6 drugs to prevent a cytokine storm, and broadspect­rum antibiotic­s to prevent secondary bacterial infections,” said Dr BK Tripathi, head of the department of medicine at New Delhi’s Safdarjung Hospital.

52,563 1,078 37,978 Madhya Pradesh

25,474

Dadar & Nagar Haveli

733

Chhattisga­rh

6,254

Maharashtr­a

50,826

Goa

4,350

Karnataka

80,863

Kerala

Bihar

31,691

Jharkhand

7,166

Odisha

21,099

Andhra Pradesh

72,711 2,420

Tamil Nadu

1,264 7,998

Puducherry

120 192,964 6,472 484 3,254

6,594

*Data compiled by covid19ind­ia.org and cross-checked from inputs by HT’S correspond­ents and news agencies. 'Cases reassigned to states' is as per data released by the MOHFW. This figure has not been included in the calculatio­n for the daily new cases.

16,110 28 347,502

Telangana

632 286 9,895 174 474 5,030 29,310 1,078 17,359

4,377 2,655

194,253 1,625 1,400

136,793

 ?? BIPLOV BHUYAN/HT ?? Not all patients need plasma therapy, say experts. n
BIPLOV BHUYAN/HT Not all patients need plasma therapy, say experts. n

Newspapers in English

Newspapers from India